ÄÁÆÛ·±½º ÇÁ·Î±×·¥

°øÇÐ ½ºÆ®¸²
- Display of Biologics
¹ÙÀÌ¿À·ÎÁ÷½ºÀÇ µð½ºÇ÷¹ÀÌ - Engineering Antibodies
Ç×ü °øÇÐ - Machine Learning Part 2
±â°èÇнÀ ÆÄÆ® 2

Ÿ°Ù ½ºÆ®¸²
- Antibody-Based Therapies
Ç×ü ±â¹Ý ÀǾà - Emerging Targets
½Å±Ô Ÿ°Ù - Membrane Protein Targets
¸·´Ü¹éÁú Ÿ°Ù

ÀÌÁ߯¯À̼º ½ºÆ®¸²
- Safety & Efficacy
¾ÈÀü¼º¡¤À¯È¿¼º - Advancing Multispecifics
´ÙÁß Æ¯À̼º Ç×üÀÇ Áøº¸ - Engineering Bispecifics
ÀÌÁ߯¯À̼ºÇ×ü °øÇÐ

¸é¿ªÄ¡·á ½ºÆ®¸²
- Immunoengineering
¸é¿ª °øÇÐ - Innovative CAR Therapy
Çõ½ÅÀûÀÎ CAR ¿ä¹ý - Next-Gen Immunotherapies
Â÷¼¼´ë ¸é¿ªÄ¡·á

ºÐ¼®¹ý ½ºÆ®¸²
- Optimisation & Developability
ÃÖÀûÈ¡¤°³¹ß °¡´É¼º - Analytical Characterisation
ºÐ¼®¹ý Ư¼º Æò°¡ - Protein Stability & Formulation
´Ü¹éÁú ¾ÈÁ¤¼º¡¤Á¦Çü

¹ßÇö ½ºÆ®¸²
- Leveraging Data Science
µ¥ÀÌÅÍ »çÀ̾𽺠Ȱ¿ë - Optimising Expression
¹ßÇö ÃÖÀûÈ - Developing Workflows
¿öÅ©ÇÃ·Î¿ì °³¹ß

±â°èÇнÀ ½ºÆ®¸²
- Intro to Machine Learning
±â°èÇнÀ ÀÔ¹® - Machine Learning Part 1
±â°èÇнÀ ÆÄÆ® 1 - Machine Learning Part 2
±â°èÇнÀ ÆÄÆ® 2

Á¾¾ç ½ºÆ®¸²
- Antibody-Based Therapies
Ç×ü ±â¹Ý ÀǾà - Engineering ADCs
ADC °øÇÐ - Next-Gen Immunotherapies
Â÷¼¼´ë ¸é¿ªÄ¡·á